{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000044","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.051023+00:00","generated_at":"2026-05-24T03:54:43.210671+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete","bullets":["Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.","Cash, equivalents and marketable securities $231.5M, down from $306.1M; runway into H1 2027.","Phase 2 ALTITUDE-AD enrolled 542 early AD patients; topline results expected late 2026.","Phase 1 subcutaneous sabirnetug showed mild injection-site reactions; supports further SC development.","JPAD published Phase 1 INTERCEPT-AD results; sabirnetug well-tolerated with dose-dependent target engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000044","json":"https://secwatch.observer/filing/0001576885-25-000044.json","markdown":"https://secwatch.observer/filing/0001576885-25-000044.md","text":"https://secwatch.observer/filing/0001576885-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/0001576885-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:54:43.210671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}